STOCKS TELEGRAPH

Tag: APVO stock

  • Aptevo (APVO) Gains Pre-Hour Boost On Encouraging AML Treatment Efficacy

    Aptevo (APVO) Gains Pre-Hour Boost On Encouraging AML Treatment Efficacy

    Aptevo Therapeutics Inc. (NASDAQ: APVO) is witnessing a substantial surge in share value during Wednesday’s pre-market session, rising 152.84% to $7.13. The stock’s sharp increase follows the company’s announcement of updated clinical-trial data.

    Clinical Breakthrough

    Aptevo Therapeutics shared data from its Phase 1b/2 RAINIER trial of mipletamig—a first-in-class CD123 x CD3 bispecific antibody being tested in combination with standard therapies venetoclax and azacitidine (ven/aza) in patients newly diagnosed with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.

    Exceptional Remission Rates in Frontline AML

    According to Aptevo, the combination therapy demonstrated remission in 85% of evaluable frontline AML patients across two studies. This rate notably surpasses outcomes seen in comparator trials such as the Viale A study, which evaluated ven/aza alone.

    The first two patient cohorts showed encouragingly no signs of cytokine release syndrome (CRS), a common and severe adverse effect in many immunotherapies. Nearing full enrollment is Cohort 3, which is evaluating the greatest dosage level to yet.

    Strategic Innovation Behind Mipletamig

    The high efficacy and favorable safety data are credited to Aptevo’s proprietary CD3 engineering platform. Mipletamig uniquely utilizes the CRIS-7 binding domain, a strategic design intended to reduce cytokine-driven toxicity while maintaining potent anti-cancer activity.

    This engineering approach not only underpins mipletamig’s current success but is also expected to strengthen future candidates in Aptevo’s pipeline, such as its preclinical prostate cancer therapy, APVO442.

    Redefining AML Therapy for Unfit Patients

    AML is a particularly aggressive blood cancer, with limited options and generally poor outcomes for elderly or medically unfit patients. Aptevo’s findings suggest that mipletamig may offer a new, more effective, and better-tolerated frontline therapy.

    With 85% remission achieved—three of which were in patients with high-risk genetic profiles—Aptevo (APVO) positions mipletamig as a promising candidate to redefine treatment paradigms and elevate standards of care in a historically underserved population.

  • Aptevo (APVO) Sees Significant Market Rally After Equity Offering

    Aptevo (APVO) Sees Significant Market Rally After Equity Offering

    Aptevo Therapeutics Inc. (NASDAQ: APVO) shares are on a remarkable surge of 44.98% as of the last check today, reaching $2.01. This sharp increase in APVO stock follows a pivotal equity offering move by the biotechnology company, reinforcing investor confidence in its ongoing strategic initiatives.

    Registered Direct Offering

    Definitive securities purchase agreements for the issue of 1,764,710 shares of Aptevo Therapeutics’ common stock in a registered direct offering have been concluded. Concurrently, APVO has issued warrants to purchase up to 3,529,420 additional shares in a private placement. The total purchase price for each share and associated warrant is fixed at $1.19.

    The warrants will be exercisable after shareholder approval and will be valid for five years after the initial exercise date. They have an exercise price of $1.19 per share. With the fulfillment of standard closing conditions, the offering is expected to close on or around April 4, 2025.

    Before subtracting placement agency fees and related offering expenses, Aptevo expects to make around $2.1 million in gross proceeds. The money will go toward working capital, basic business needs, and the ongoing clinical development of its pharmaceutical prospects.

    Positive Clinical Advancements

    In a significant clinical advancement, Aptevo Therapeutics recently reported that two additional frontline acute myeloid leukemia (AML) patients have achieved remission within 30 days of treatment in its RAINIER dose optimization trial. The study evaluates the effectiveness of mipletamig in combination with the standard of care for patients unfit for intensive chemotherapy.

    The latest data reinforces the promising results from Cohort 1 and the prior dose expansion trial, where all frontline patients attained remission. With these interim findings, mipletamig has demonstrated a compelling overall remission rate of 90% among frontline patients.

    Future Prospects

    Aptevo Therapeutics continues to see very positive remission rates in Cohort 2 of the RAINIER study, which has now crossed the halfway point. These findings highlight the potential benefits of mipletamig for AML patients who would ordinarily require venetoclax plus azacitidine as the conventional treatment but are not eligible for intense chemotherapy.

    Aptevo is still committed to proving the effectiveness of mipletamig’s distinct mode of action in combination treatment. This strategy supports APVO’s efforts to develop cutting-edge treatments for AML and shows promise, especially for older patients with few therapy alternatives.

  • Aptevo Therapeutics (APVO) Sees Spectacular Rise Push on to Pre-market Session

    Aptevo Therapeutics Inc. (NASDAQ: APVO) experienced a whirlwind of activity on Wednesday, with its stock soaring an impressive 35%. Yet, the excitement didn’t stop there. In the early premarket hours on Thursday, APVO witnessed an additional staggering leap of 49%, reaching a high of $1.43.

    What’s Driving the Surge?

    Despite the lack of apparent news fueling this surge, speculations abound. Many investors are speculating about potential insider accumulation, hinting at undisclosed positive catalysts on the horizon. This mystery behind the surge has left some wary, fearing an impending profit-taking dip in the coming days. However, for now, bullish sentiment prevails as investors ride the wave of optimism.

    Aptevo Therapeutics: Pioneering Immunotherapies

    Aptevo Therapeutics, Inc. stands as a beacon in the realm of biotechnology, particularly in the field of cancer treatment. The company focuses on developing innovative immunotherapies to combat various forms of cancer. Its robust pipeline includes promising candidates like APVO436, ALG.APV-527, APVO603, and APVO442, developed leveraging cutting-edge ADAPTIR modular protein platform technology.

    The recent surge in APVO’s stock value coincides with significant updates shared by the company’s CEO in a letter to shareholders. The letter highlighted the remarkable progress made in advancing clinical programs, notably the encouraging durability of remission data from the APVO436 Phase 1b dose expansion trial. This data, showcasing impressive patient responses and safety profiles, underscores the potential of APVO436 to enhance the standard of care for Acute Myeloid Leukemia (AML) patients.

    Moreover, ongoing trials evaluating ALG.APV-527 for the treatment of multiple solid tumor types have shown promising early results. Notably, the drug’s ability to induce stable disease in heavily pretreated breast cancer patients signifies a significant breakthrough in cancer therapeutics.

    In Conclusion

    As Aptevo Therapeutics continues its pioneering work in cancer immunotherapy, investors eagerly anticipate further developments in its clinical programs. With promising candidates like APVO436 and ALG.APV-527 demonstrating encouraging results, the company remains at the forefront of innovation in cancer treatment.

    As the market awaits upcoming trial milestones and potential positive catalysts, optimism surrounding Aptevo Therapeutics continues to grow, fueled by the promise of creating a brighter future for cancer patients worldwide.

  • Aptevo Therapeutics (APVO) Faces Sharp Decline in Premarket Trading

    Aptevo Therapeutics Inc. (NASDAQ: APVO) experienced a tumultuous Wednesday as its stock price took a staggering 26% nosedive, plummeting from $3.26 to $2.40. However, the woes for investors didn’t end there.

    In the early premarket hours on Thursday, APVO continued its downward spiral, plunging a further 42% to as low as $1.40. The drastic drop was accompanied by a surge in trading volume, which doubled the average. This sudden and severe decline has left many investors scrambling to unload their APVO holdings.

    Pipeline Updates

    The sharp downturn coincides with significant updates from the company regarding its pipeline. Aptevo Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing novel immunotherapies for cancer treatment. Its pipeline includes promising candidates such as APVO436, ALG.APV-527, APVO603, and APVO442, developed using innovative modular protein platform technologies.

    Recent announcements have highlighted advancements in clinical programs and preclinical developments:

    ALG.APV-527 Phase 1 Trial

    • A patient transitioned from progressive disease to long-lasting stable disease, marking a significant milestone in cancer treatment research.
    • The trial is more than 50% enrolled, with dosing in cohort five (of six) imminent.

    Phase 1b/2 Trial for APVO436

    • Scheduled to commence in the first half of 2024.
    • Aimed at evaluating APVO436 for the treatment of acute myeloid leukemia (AML) in combination therapy.

    APVO711 Preclinical Progress

    • Promising results indicate potential for targeting a broad range of solid tumors.
    • APVO711 shows the dual mechanism of action functionality, offering new hope for patients in need of more effective treatments.

    Dr. Dirk Huebner, Chief Medical Officer at Aptevo, expressed optimism about ALG.APV-527’s potential, citing the uncommon but therapeutically promising outcome observed in the trial. Additionally, the company is poised to initiate a Phase 1b/2 trial for APVO436 in the first half of 2024, further underscoring its commitment to advancing cancer therapeutics.

    Furthermore, APVO711, a bispecific checkpoint inhibitor, has shown promising preclinical results, with the company’s robust financial position providing a solid foundation for future developments. With approximately $16 per share in cash reserves, Aptevo is well-positioned to navigate the challenges and opportunities in the biotechnology landscape.

    Conclusion

    In conclusion, while Aptevo Therapeutics Inc. grapples with a significant decline in premarket trading, its commitment to advancing innovative cancer therapies remains unwavering. Investors are closely monitoring developments in its pipeline, recognizing the potential for long-term growth amid the current market volatility.

  • What changed for these 50 stocks in Pre-Market Session?

    What changed for these 50 stocks in Pre-Market Session?

    Oncternal Therapeutics Inc. (ONCT) stock soared 2.42% to $2.96 in the pre-market trading as the company raised the size of the formerly publicized offering and purchase on a firm commitment basis 7,258,065 shares of common stock of the Company, at a price to the public of $3.10 per share, less underwriting discounts, and commissions.

    JOYY Inc. (NASDAQ: YY) shares are trading up 19.13% at $87.75 at the time of writing as the Company revealed its Q3, 2020 Earnings. Analysts have a consensus price target of $125. The company’s 52-week range was noted as $41.33 to $108.21.

    Aptevo Therapeutics Inc. (APVO) grew over 38.17% at $48.9 in pre-market trading today after the firm offered an update on ALG.APV-527, a novel immunotherapeutic bispecific candidate aimed for the cure of multiple solid tumors expressing 5T4, a tumor-restricted antigen.

    Zomedica Pharmaceuticals Corp. (ZOM), a Drug Manufacturers – Specialty & Generic company, dropped about -2.19% at $0.1428 in pre-market trading Thursday as the firm announced its Q3 2020 results.

    Nxt-ID Inc. (NXTD) stock moved down -1.99 percent to $0.35 in the pre-market trading after the Corporation declared to adjourn the annual meeting of shareholders.

    MoneyGram International Inc. (MGI) lost over -7.9% at $6.7 in pre-market trading Thursday 19 November 2020, as the company posted 150% year-over-year cross-border deal and revenue growth for October in its direct-to-consumer digital business, MGO.

    Lexicon Pharmaceuticals Inc. (LXRX) is up more than 2.5% at $1.64 in pre-market hours Thursday 19 November 2020 following the company revealed to participate in Stifel 2020 Virtual Healthcare conference on Wednesday, November 18, 2020. The stock had dropped over -11.60% to $1.60 in the last trading session.

    Before the trading started on 19 November 2020, UP Fintech Holding Limited (TIGR) is up 4.61% to reach $5.9 after the Company announced to unveil its quarterly results on November 25, 2020. It has been trading in a 52-week range of $2.03 to $7.60.

    Asia Pacific Wire & Cable Corporation Limited (APWC) stock plunged -4.72% to $2.02 in the pre-market trading as the Corporation publicized that it will organize its 2020 Annual General Meeting on September 18, 2020, at 9:00 a.m. New York time at its headquarters located at Room B, 15th Floor, No. 77, Section 2, Dunhua South Road, Taipei, 106, Taiwan and (2) the Company has procured a US$6,000,000 secured loan from its majority shareholder, Pacific Electric Wire & Cable Co., Ltd.

    Marathon Patent Group Inc. (NASDAQ: MARA) shares are trading down -0.35% at $2.88 at the time of writing following Bitcoin self-mining company has disclosed a new investor presentation, which contains updated economic information as of November 5, 2020. The company’s 52-week range was noted as $0.35 to $5.25. Analysts have a consensus price target of $8.

    Futu Holdings Limited (FUTU) grew over 10.7% at $47.6 in pre-market trading today after the company publicized its 3rd quarter scores.

    L Brands Inc. (LB), and Apparel Retail company, rose about 16.04% at $39.0 in pre-market trading Thursday as the firm announced upbeat earnings results.

    Agora Inc. (API) stock moved up 2.45 percent to $35.99 in the pre-market trading after the Tech-giant announced its Q3 2020 results.

    ObsEva SA (OBSV) gained over 3.38% at $2.14 in pre-market trading Thursday 19 November 2020 as the biotech-firm declared the positive topline results of PROLONG, the Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled trial of laropiprant in preterm labor.

    Bilibili Inc. (BILI) is up more than 4.49% at $50.0 in pre-market hours Thursday 19 November 2020, after the Corporation revealed its third-quarter 2020 results. The stock had dropped over -4.40% to $47.85 in the last trading session.

    Before the trading started on 19 November 2020, Youdao Inc. (DAO) is up 3.9% to reach $26.13, as it revealed quarterly results for the fiscal third quarter. It has been trading in a 52-week range of $13.20 to $47.70.

    Oragenics Inc. (OGEN) stock plunged -6.27% to $0.4377 in pre-market trading.

    SPI Energy Co. Ltd. (NASDAQ: SPI) shares are trading up 3.51% at $8.25 at the time of writing, as the Energy sector firm announced that its completely-owned SPI Solar, subsidiary completed the sale of a 1.015-megawatt solar project located on Hawaii’s Maui island. The company’s 52-week range was noted as $0.55 to $46.67.

    Gold Fields Limited (GFI) tumbled over -3.19% at $9.42 in pre-market trading today, following the Company revealed operational details for the 3-month period ending September 30, 2020.

    Marin Software Incorporated (MRIN), a Software – Application company, dropped about -3.38% at $2.0 in pre-market trading Thursday.

    X Financial (XYF) stock moved up 99.14 percent to $1.39 in the pre-market trading as the company disclosed that it will hold its 2020 annual general meeting of shareholders at its offices at 7/F, Block A, Aerospace Science and Technology Plaza, No.168 Haide Third Avenue, Nanshan District, Shenzhen, China on December 11, 2020, at 10:00 a.m., Beijing Time.

    Simon Property Group Inc. (SPG) lost over -2.43% at $74.75 in pre-market trading Thursday 19 November 2020 after the news that Simon has valued an upsized public offering of 19,250,000 shares of common stock at a public offering price of $72.50 per share that is expected to close November 23, 2020, subject to the satisfaction of customary closing conditions.

    ZoomInfo Technologies Inc. (ZI) is up more than 2.55% at $40.6 in pre-market hours Thursday 19 November 2020, as the Company revealed its Q3 2020 Earnings results. The stock had dropped over -2.85% to $39.59 in the last trading session.

    Before the trading started on 19 November 2020, Pan American Silver Corp. (PAAS) is down -2.98% to reach $29.98, after the Company Q3 results matched the predictions. It has been trading in a 52-week range of $10.61 to $40.11.

    Leap Therapeutics Inc. (LPTX) stock soared 6.67% to $1.6 in the pre-market trading, as the Company posted Q3 2020 Earnings results. The most recent rating by Piper Sandler, on June 29, 2020, is at an Overweight.

    Hudson Capital Inc. (NASDAQ: HUSN) shares are trading up 33.93% at $3.0 at the time of writing, following news of Hudson Capital Inc. and FreightHub, Inc. progressing further with the planned merger. The company’s 52-week range was noted as $1.60 to $9.80.

    Transocean Ltd. (RIG) grew over 4.07% at $1.28 in pre-market trading today, as the firm reported deep-water Corcovado, deep water Mykonos contract extensions.

    Acasti Pharma Inc. (ACST), a Biotechnology company, rose about 4.55% at $0.23 in pre-market trading Thursday, after the firm revealed Q2, 2021 fiscal results.

    Orbital Energy Group Inc. (OEG) stock moved up 3.56 percent to $0.8 in the pre-market trading, as the company posted Q3, 2020 earnings reports.

    Ideanomics Inc. (IDEX) gained over 10.34% at $1.28 in pre-market trading Thursday 19 November 2020 after the firm announced MEG October & Q4 sales activity.

    Virgin Galactic Holdings Inc. (SPCE) is up more than 2.04% at $23.05 in pre-market hours Thursday 19 November 2020 after the Analysts decreased its estimates by almost 25%. The stock had jumped over 5.81% to $22.59 in the last trading session.

    Before the trading started on 19 November 2020, Washington Prime Group Inc. (WPG) is down -2.15% to reach $0.742 after the report of the company to present at REITworld 2020 Virtual Investor Conference. It has been trading in a 52-week range of $0.49 to $4.49.

    Kintara Therapeutics Inc. (KTRA) stock soared 1.79% to $1.71 in the pre-market trading, after the company announced Q1, 2021 results and offered a business update.

    Electra Meccanica Vehicles Corp. (NASDAQ: SOLO) shares are trading up 7.53% at $7.43 at the time of writing. The company’s 52-week range was noted as $0.89 to $7.91.

    K12 Inc. (LRN) grew over 6.56% at $25.49 in pre-market trading today.

    Polar Power Inc. (POLA), an Electrical Equipment & Parts company, dropped about -3.35% at $3.46 in pre-market trading Thursday.

    Ayro Inc. (AYRO) stock moved up 3.77 percent to $4.4 in the pre-market trading, after the company revealed its Q3, 2020 fiscal results.

    Jaguar Health Inc. (JAGX) gained over 5.82% at $0.22 in pre-market trading Thursday 19 November 2020, following the announcement of its third-quarter 2020 financial scores.

    Sanchez Midstream Partners LP (SNMP) is down more than 0.0% at $0.5951 in pre-market hours Thursday 19 November 2020. The stock had jumped over 11.03% to $0.60 in the last trading session.

    Before the trading started on 19 November 2020, Waitr Holdings Inc. (WTRH) is up 6.46% to reach $3.38, as the company’s earnings results topped estimates. It has been trading in a 52-week range of $0.26 to $5.85.

    GreenPower Motor Company Inc. (GP) stock plunged -1.07% to $18.49 in the pre-market trading, after the report that Thermalito Union Elementary School District Agrees on purchase of six all-electric school buses from GreenPower. The most recent rating by Maxim Group, on November 02, 2020, is a Buy.

    Arcimoto Inc. (FUV) grew over 0.74% at $9.51 in pre-market trading today, after the company revealed its Q3, 2020 results, and business update.

    Kandi Technologies Group Inc. (KNDI), an Auto Manufacturers company, rose about 11.55% at $12.65 in pre-market trading Thursday, November 19, 2020, after the report that Kandi America’s EV qualified for $2,500 refund in Texas.

    China HGS Real Estate Inc. (HGSH) gained over 11.17% at $1.99 in pre-market trading Thursday 19 November 2020.

    VAALCO Energy Inc. (EGY) is down more than -9.63% at $1.22 in pre-market hours Thursday 19 November 2020, after the company revealed that it has signed a sale and purchase agreement to acquire Sasol Gabon S.A.’s 27.8% working interest in the Etame Marin block offshore Gabon. The stock had jumped over 32.35% to $1.35 in the last trading session.

    Before the trading started on 19 November 2020, Kazia Therapeutics Limited (KZIA) is down -7.87% to reach $12.41, as the announcement was made that it has executed a definitive contract with the International Coalition for Adaptive Research (GCAR) to commence Kazia’s participation in the GBM AGILE pivotal study in glioblastoma. It has been trading in a 52-week range of $2.47 to $11.10.

    Naked Brand Group Limited (NAKD) stock soared 39.0% to $0.18 in the pre-market trading.

    Phoenix Tree Holdings Limited (NYSE: DNK) shares are trading down -18.6% at $3.72 at the time of writing. The company’s 52-week range was noted as $1.27 to $13.90.